Open Access<p>Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration</p>
Author(s) -
Balaji Veluswamy,
Andy Hung-Yi Lee,
Rukhsana G. Mirza,
Manjot K. Gill
Publication year - 2020
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s256009
Subject(s) - medicine , macular degeneration , ranibizumab , aflibercept , ophthalmology , bevacizumab , visual acuity , retrospective cohort study , cohort , surgery , chemotherapy
Neovascular age-related macular degeneration (nv-AMD) is the leading cause of blindness in individuals 55 years and older. The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has greatly altered the visual acuity (VA) prognosis in these patients. While many studies have described treatment outcomes, few have explored the impact of early detection on VA outcomes.